Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4Ra antibody, is required to broadly inhibit type 2 inflammation
Ontology highlight
ABSTRACT: Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4Ra antibody, is required to broadly inhibit type 2 inflammation
PROVIDER: PRJNA591357 | ENA |
REPOSITORIES: ENA
ACCESS DATA